News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
NanoViricides, Inc. announces that its antiviral drug candidate NV-387 shows promise in combating potential bird flu pandemic. The drug mimics essential host-side features, making it hard for the virus to escape -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
NanoViricides, Inc. files Quarterly Report on Form 10-Q with the SEC, highlights financial results and progress on NV-387 antiviral drug for various infections including MPox and RSV
